Effect of zoledronate ( a medicine that decreases bone loss ) in bone loss occurring in patients with liver disease
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Chronic liver diseaseHealth Condition 2: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2018/02/011761
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 36
Inclusion Criteria
Lumbar spine Z score less than or equal to -2
Exclusion Criteria
1. Child C cirrhosis
2. Chronic Kidney disease
3.. Current steroid use
4. Primary Hyperparathyroidism
5. Cushing Syndrome
6. Malignancies (Except Hepatocellular Carcinoma)
7. HIV infection
8. Current vertebral fractures
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the effect of zoledronate on change in bone mineral density at lumbar spine in male patients with hepatic osteodystrophy at 12 months follow upTimepoint: 6 & 12 months
- Secondary Outcome Measures
Name Time Method To evaluate the incidence of new fractures at 12 monthsTimepoint: 6 & 12 months;To study the effect of zoledronate on change in biochemical markers of bone turnoverTimepoint: 6 & 12 months;To study the effect of zoledronate on change in bone mineral density at total hip &neck of femur in male patients with hepatic osteodystrophyTimepoint: 6 & 12 months